Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers. However, anti–PD-1 therapy in some patients provides no benefit and/or results in adverse side effects. The factors that...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Invest
Glavni autori: Mehnert, Janice M., Panda, Anshuman, Zhong, Hua, Hirshfield, Kim, Damare, Sherri, Lane, Katherine, Sokol, Levi, Stein, Mark N., Rodriguez-Rodriquez, Lorna, Kaufman, Howard L., Ali, Siraj, Ross, Jeffrey S., Pavlick, Dean C., Bhanot, Gyan, White, Eileen P., DiPaola, Robert S., Lovell, Ann, Cheng, Jonathan, Ganesan, Shridar
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2016
Teme:
Brief Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4887167/
https://ncbi.nlm.nih.gov/pubmed/27159395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI84940
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items